2024-09-18 - Analysis Report
## JNJ Stock Analysis Report

**Company Overview:**  Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**

JNJ's cumulative return of 20.59% is significantly lower than the S&P 500's return of 89.02%, resulting in a -68.43% performance gap.  This places JNJ at the 14.36% percentile of its historical performance range against the S&P 500, indicating relatively weaker performance.

**2. Recent Price Action:**

| Period | Moving Average |
|---|---|
| 5 days | 165.87 |
| 20 days | 164.46 |
| 60 days | 157.45 |

The current price of 166.99 is above all three moving averages, suggesting potential short-term upside. However, the 60-day moving average is significantly lower, implying a longer-term downtrend. 

**3. Technical Indicators:**

* **RSI (56.94):** The RSI indicates JNJ is in a slightly overbought territory, suggesting potential for a short-term pullback.
* **PPO (-0.14):** The PPO indicates a slight bearish momentum, consistent with the RSI.
* **Delta_Previous_Relative_Divergence (3.12):** The positive value signifies a potential short-term uptrend, despite the slightly bearish RSI and PPO readings.
* **Expected Return (11.76%):** This represents the potential 5-year expected return on investment, suggesting potential for long-term growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

The most recent earnings (2024-07-25) were 1.95, which **slightly surpassed analyst estimates**, indicating a positive earnings surprise. Revenue of 22.45 B$ also showed an increase compared to previous quarters.  While this quarter's results suggest a positive trend, it's crucial to monitor future earnings to confirm sustainable growth.

**5. Overall Analysis:**

JNJ is currently trading at a discount to the market, which could be an attractive entry point for long-term investors seeking a dividend-paying stock with a history of consistent earnings. Despite recent positive earnings results, its underperformance relative to the broader market and the slightly bearish technical indicators suggest cautious optimism. Long-term investors with a high risk tolerance and a focus on dividend income could consider adding JNJ to their portfolio.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Consult with a qualified financial advisor before making any investment decisions. 
